GN 1140

Drug Profile

GN 1140

Alternative Names: Gd-DTPA-DeA

Latest Information Update: 05 Nov 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Contrast media
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Liver metastases

Most Recent Events

  • 05 Nov 2003 No development reported - Phase-II for Liver metastases (diagnosis) in Japan (IV)
  • 02 Jul 2002 A study has been added to the Cancer therapeutic trials section
  • 06 Mar 2001 Phase-II clinical trials for Liver metastases (diagnosis) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top